Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Comparing Copy Number Variations and SNPs02:26

Comparing Copy Number Variations and SNPs

Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antiaromaticity-Driven Enhancement of Single-Molecule Electrical Conductance by s-Indacene Molecular Bridges.

Angewandte Chemie (International ed. in English)·2026
Same author

Anatomic variations uncommon variant of the callosomarginal artery originating from A1 segment of the anterior cerebral artery with an unruptured aneurysm and distal A1 fenestration.

Surgical and radiologic anatomy : SRA·2026
Same author

Pharmacist Intervention Preventing Severe Cytokine Release Syndrome Induced by Immune Checkpoint Inhibitor Therapy: A Case Report.

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·2026
Same author

Venous Anatomy and Embryology of the Tentorium.

Journal of neuroendovascular therapy·2026
Same author

Healthy aging and aging-related kidney diseases: lessons from centenarians.

Clinical kidney journal·2025
Same author

Whole-genome sequencing of 3135 individuals representing the genetic diversity of the Japanese population.

Journal of human genetics·2025

Related Experiment Video

Updated: Jul 3, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

An optimal dose-effect mode trend test for SNP genotype tables.

Ryo Yamada1, Yukinori Okada

  • 1Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan. ryamada@src.riken.go.jp

Genetic Epidemiology
|August 9, 2008
PubMed
Summary

Genome-wide association studies (GWAS) analyze complex traits using contingency tables. A new statistic improves power by testing for optimal allele dose-effects between recessive and dominant modes.

More Related Videos

Infinium Assay for Large-scale SNP Genotyping Applications
13:33

Infinium Assay for Large-scale SNP Genotyping Applications

Published on: November 19, 2013

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Related Experiment Videos

Last Updated: Jul 3, 2026

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

Infinium Assay for Large-scale SNP Genotyping Applications
13:33

Infinium Assay for Large-scale SNP Genotyping Applications

Published on: November 19, 2013

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Area of Science:

  • Genetics
  • Statistical Genetics

Background:

  • Genome-wide association studies (GWAS) are crucial for understanding complex trait genetics.
  • Standard statistical tests (e.g., trend, genotype, dominant, recessive modes) are used with two-by-three contingency tables in GWAS.
  • Existing tests or combinations may not be optimal for all genetic models.

Purpose of the Study:

  • To describe the relationships among existing statistical tests used in GWAS.
  • To propose a novel statistic that enhances the power of detecting genetic associations.
  • To test hypotheses regarding allele dose-effects between recessive and dominant modes.

Main Methods:

  • Analysis of relationships between chi-squared tests (df=2, df=1 for dominant/recessive modes) and the trend test (df=1 for additive mode).
  • Development of a new statistic based on these relationships.
  • Hypothesis testing for disease-susceptible allele dose-effects.

Main Results:

  • Established the interrelations among common GWAS statistical tests.
  • Proposed a new statistic that captures dose-effects optimally.
  • The new statistic effectively tests for intermediate allele effects.

Conclusions:

  • The proposed statistic offers improved power for detecting genetic associations in GWAS.
  • It provides a more nuanced approach to modeling allele effects beyond simple additive, dominant, or recessive models.
  • This advancement can lead to better identification of genetic variants influencing complex traits.